Delaying implementation of the Clinical Laboratory Fees Schedule; Support Local Coverage Determination process legislation; Concern about FDA regulation of clinical labs; Authorization of the 4K score test for prostrate cancer; MAC review of lab testing
Delaying implementation of the Clinical Laboratory Fees Schedule; Support Local Coverage Determination process legislation; Concern about FDA regulation of clinical labs; Authorization of the 4K score test for prostrate cancer; MAC review of lab testing; prior authorization of genetic testing
Delaying implementation of the Clinical Laboratory Fees Schedule; Support Local Coverage Determination process legislation; Concern about FDA regulation of clinical labs; Authorization of the 4K score test for prostrate cancer; MAC review of lab testing; National Coverage decision on genetic testing.
Duration: January 14, 2017
to
January 15, 2019
General Issues: Health Issues , Government Issues , Medical/Disease Research/Clinical Labs
Spending: about $345,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2017: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2019
Carmen Group Incorporated terminated an engagement in which they represented BioReference Laboratories, Inc. on Jan. 18, 2019.
Original Filing: 301008536.xml
4th Quarter, 2018
In Q4, Carmen Group Incorporated lobbied for BioReference Laboratories, Inc. , earning $30,000. The report was filed on Jan. 18, 2019.
Original Filing: 301008519.xml
Lobbying Issues
Delaying implementation of the Clinical Laboratory Fees Schedule; Support Local Coverage Determination process legislation; Concern about FDA regulation of clinical labs; Authorization of the 4K score test for prostrate cancer; MAC review of lab testing
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Delaying implementation of the Clinical Laboratory Fees Schedule; Support Local Coverage Determination process legislation; Concern about FDA regulation of clinical labs; Authorization of the 4K score test for prostrate cancer; MAC review of lab testing; prior authorization of genetic testing
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Delaying implementation of the Clinical Laboratory Fees Schedule; Support Local Coverage Determination process legislation; Concern about FDA regulation of clinical labs; Authorization of the 4K score test for prostrate cancer; MAC review of lab testing; National Coverage decision on genetic testing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2018
In Q3, Carmen Group Incorporated lobbied for BioReference Laboratories, Inc. , earning $45,000. The report was filed on Oct. 19, 2018.
Original Filing: 300991045.xml
Lobbying Issues
Delaying implementation of the Clinical Laboratory Fees Schedule; Support Local Coverage Determination process legislation; Concern about FDA regulation of clinical labs; Authorization of the 4K score test for prostrate cancer; MAC review of lab testing
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Delaying implementation of the Clinical Laboratory Fees Schedule; Support Local Coverage Determination process legislation; Concern about FDA regulation of clinical labs; Authorization of the 4K score test for prostrate cancer; MAC review of lab testing; prior authorization of genetic testing
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Delaying implementation of the Clinical Laboratory Fees Schedule; Support Local Coverage Determination process legislation; Concern about FDA regulation of clinical labs; Authorization of the 4K score test for prostrate cancer; MAC review of lab testing; National Coverage decision on genetic testing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2018
In Q2, Carmen Group Incorporated lobbied for BioReference Laboratories, Inc. , earning $45,000. The report was filed on July 17, 2018.
Original Filing: 300966875.xml
Lobbying Issues
Delaying implementation of the Clinical Laboratory Fees Schedule; Support Local Coverage Determination process legislation; Concern about FDA regulation of clinical labs; Authorization of the 4K score test for prostrate cancer; MAC review of lab testing
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Government Issues
Lobbying Issues
Delaying implementation of the Clinical Laboratory Fees Schedule; Support Local Coverage Determination process legislation; Concern about FDA regulation of clinical labs; Authorization of the 4K score test for prostrate cancer; MAC review of lab testing; National Coverage decision on genetic testing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2018
In Q1, Carmen Group Incorporated lobbied for BioReference Laboratories, Inc. , earning $45,000. The report was filed on April 19, 2018.
Original Filing: 300950563.xml
Lobbying Issues
Delaying implementation of the Clinical Laboratory Fees Schedule; Support Local Coverage Determination process legislation; Concern about FDA regulation of clinical labs; Authorization of the 4K score test for prostrate cancer; MAC review of lab testing
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Government Issues
Lobbying Issues
Delaying implementation of the Clinical Laboratory Fees Schedule; Support Local Coverage Determination process legislation; Concern about FDA regulation of clinical labs; Authorization of the 4K score test for prostrate cancer; MAC review of lab testing; National Coverage decision on genetic testing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2017
In Q4, Carmen Group Incorporated lobbied for BioReference Laboratories, Inc. , earning $45,000. The report was filed on Jan. 19, 2018.
Original Filing: 300929120.xml
Lobbying Issues
Delaying implementation of the Clinical Laboratory Fees Schedule; Support Local Coverage Determination process legislation; Concern about FDA regulation of clinical labs; Authorization of the 4K score test for prostrate cancer; MAC review of lab testing
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Government Issues Medical/Disease Research/Clinical Labs
3rd Quarter, 2017
In Q3, Carmen Group Incorporated lobbied for BioReference Laboratories, Inc. , earning $45,000. The report was filed on Oct. 19, 2017.
Original Filing: 300910105.xml
Lobbying Issues
Delaying implementation of the Clinical Laboratory Fees Schedule; Support Local Coverage Determination process legislation; Concern about FDA regulation of clinical labs; Authorization of the 4K score test for prostrate cancer; MAC review of lab testing
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Government Issues Medical/Disease Research/Clinical Labs
2nd Quarter, 2017
In Q2, Carmen Group Incorporated lobbied for BioReference Laboratories, Inc. , earning $45,000. The report was filed on July 19, 2017.
Original Filing: 300890277.xml
Lobbying Issues
Delaying implementation of the Clinical Laboratory Fees Schedule; Support Local Coverage Determination process legislation; Concern about FDA regulation of clinical labs; Authorization of the 4K score test for prostrate cancer; MAC review of lab testing
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Government Issues Medical/Disease Research/Clinical Labs
1st Quarter, 2017
In Q1, Carmen Group Incorporated lobbied for BioReference Laboratories, Inc. , earning $45,000. The report was filed on April 20, 2017.
Original Filing: 300873872.xml
Lobbying Issues
Delaying implementation of the Clinical Laboratory Fees Schedule; Support Local Coverage Determination process legislation; Concern about FDA regulation of clinical labs; Authorization of the 4K score test for prostrate cancer; MAC review of lab testing
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Government Issues Medical/Disease Research/Clinical Labs
1st Quarter, 2017
Carmen Group Incorporated filed a lobbying registration on March 28, 2017 to represent BioReference Laboratories, Inc., effective Jan. 14, 2017.
Original Filing: 300861967.xml
Issue(s) they said they’d lobby about: Delaying implementation of the Clinical Laboratory Fees Schedule; Support Local Coverage Determination process legislation; Concern about FDA regulation of clinical labs; Authorization of the 4K score test for prostrate cancer; MAC review of lab testing .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate